RxDoctor Payments Data

Khurrum Pirzada, DO

Family Medicine · Rochester Hills, MINPI 1750304119

Payments from drug & device makers

$12,364in general payments, 2019–2025

Across 389 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$1K
  • Lilly USA, LLC$942
  • Indivior Inc.$722
  • Novo Nordisk$599
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$586
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$12,358100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,364 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$37,143
Medicare patients
34
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$16,189
Praluent PenAlirocumab13$12,104
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$7,061
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$7,008
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl35$6,224
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med25$1,532
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine15$1,445
Rosuvastatin Calcium68$1,037
Cevimeline Hcl13$985
Atorvastatin Calcium37$665
Levothyroxine Sodium47$612
Morphine Sulfate ErMorphine Sulfate19$592
Gabapentin45$485
Sertraline Hcl52$485
Testosterone Cypionate11$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$942$16,18914 claims
Orexo US, Inc.Zubsolv$63$7,06112 claims
Indivior Inc.Suboxone$722$7,00813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →